• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us
  • Home
  • Science
  • Private: Technology
  • shARC Platform

shARC Platform

shARC Platform

"shARC platform logo"

Our shRNA armored CAR, or shARC, platform explores an armoring CAR technology in conjunction with our shRNA platform to further optimize CAR T-cell therapies for cancer patients. Armored CAR T-cells are T cells engineered to co-express a CAR and specific cytokines in order to increase their anti-tumor activity. This armoring fortifies the cell therapy to overcome the hostile tumor microenvironment (TME), characterizing most tumors, and drives a strong anti-tumor effect.

Our first armored CAR T-cell candidates are focused on the expression of Interleukin-18 (IL-18). IL-18 is a member of the IL-1 family of cytokines that plays an important role in the T-cell-helper type 1 (Th1) response, by inducing interferon (IFN) gamma production in T-cells and natural killer (NK) cells.

We believe IL-18 is an ideal cytokine for shARC as it could:

  1. directly increase the anti-cancer activity and function of CAR T-cells via an autocrine effect ;
  2. alter the balance of pro- and anti-inflammatory cells within tumor tissues via a paracrine effect, where the IL-18 cytokine can drive the strongly immunosuppressive TME to become more pro-inflammatory.
"CAR-T schema"

IL-18 can modulate not just the CAR T-cells but also the local tumor microenvironment, which can drive meaningful anti-tumor effect

shARC™ Platform to develop a series of candidates for the treatment of solid tumors and hematological malignancies

We are focusing our efforts on IL-18 for preclinical CAR T-cell candidates. In vivo data show superior anti-tumor activity with CAR T-cells secreting IL-18 compared with those not expressing IL-18. Furthermore, clinical studies using recombinant IL-18 have shown the cytokine to be well tolerated, supporting its safety for use in an armored CAR T therapy [1].

[1]. Robertson, Michael J et al. “A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma.” Journal of immunotherapy (Hagerstown, Md. : 1997) vol. 36,6 (2013): 331-41. doi:10.1097/CJI.0b013e31829d7e2e

CHECK OUR PUBLICATIONS

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use